Pfizer PFE will announce its third-quarter 2026 earnings on Nov. 3, and investors will be watching the performance of its oncology business closely, as the segment generates nearly 27% of the company's total revenues. Its key cancer medicines include Ibrance, Xtandi, Lorbrena, Braftovi/Mektovi and Padcev.
Apart from oncology, Pfizer has a broad portfolio spanning primary care, vaccines, inflammation and immunology, rare diseases and other specialty therapies. These businesses are organized under the company's Primary Care and Specialty Care segments.
Here’s a closer look at the expected third-quarter performance of Pfizer’s therapies across these two non-oncology business segments.
In Primary Care, alliance revenues and direct sales from Bristol-Myers BMY for the blood thinner Eliquis are likely to have risen, driven by higher demand trends globally, partially offset by price and generic erosion in some ex-U.S. markets. As regards sales of key vaccine Prevnar, higher sales in ex-U.S. markets are likely to have been offset by the impact of lower demand in the United States.
Pfizer records direct sales and alliance revenues from its partner, BioNTech BNTX, for the COVID-19 vaccine, Comirnaty. Revenues from Pfizer/BioNTech’s Comirnaty are likely to have declined in the third quarter due to lower U.S. utilization following narrower vaccination recommendations. Sales of the antiviral pill for COVID, Paxlovid, should also have declined due to lower infection rates, which hurt demand trends and lower international government purchases.
Sales of respiratory syncytial virus (RSV) vaccine, Abrysvo, are likely to have gained from launch uptake in some international markets, although vaccination recommendations and competition may constrain growth in United States. Favorable timing of deliveries in some international markets and favorable buying patterns in the United States benefitted sales in the second quarter, which may have reversed in the third quarter. Sales of migraine drug, Nurtec ODT/Vydura, are likely to have benefited from strong demand and prescription growth in the United States.
In the Specialty Care unit, sales of Vyndaqel are expected to have risen, as higher sales in international markets may offset lower revenues in the United States due to the impact of price erosion as a result of new payer contracts in the United States.
Sales of Xeljanz and Enbrel may have declined due to competitive and pricing pressures. In contrast, newer medicines such as Cibinqo could benefit from continued market uptake.
Pfizer’s Key Competitors
In inflammation & immunology, Pfizer’s key competitors include AbbVie, Johnson & Johnson, Amgen and Novartis. In areas such as diabetes, cardiovascular disease, obesity, and other chronic conditions, Pfizer faces competition from Eli Lilly, Novo Nordisk, Merck MRK, AstraZeneca and Sanofi. In vaccines, it competes primarily with Merck, GSK, Sanofi and Moderna.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).